Tag: VIAject(R)

JDRF Grants $407,000 to Evaluate Use of Biodel’s VIAject(R) in Treatment of Diabetes

Biodel Inc. announced the award of two research grants by the Juvenile Diabetes Research Foundation (JDRF) to Stanford University and Oregon Health & Science University (OHSU) to evaluate the use of VIAject(R) (ultra-rapid-acting injectable human insulin) in the treatment of diabetes. The first grant will support clinical testing under the direction...

FDA Accepts Biodel’s New Drug Application for Review

Biodel Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's new drug application seeking approval to market VIAject(R) for the treatment of diabetes. VIAject(R) is Biodel's proprietary formulation of recombinant human insulin that is designed to be absorbed into the blood faster than currently marketed rapid-acting insulin analogs...